wxWd~{Trru%m#97Z=}<8boK.3E@KT>1oW#!7q%7uJ?IC5 .iM!. Philippe Cartlamy, Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. DNA vaccine candidate encoding SARS-CoV-2 spike proteins elicited potent humoral and Th1 cell-mediated immune responses in mice. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19). 4b). And the GMT NAb titer against WT (Wuhan-Hu1) in the CoronaVac-prime/ChulaCov19-boost group was also 7-fold higher than 2-dose of the CoronaVac group (GMT of micro-VNT50 were 23,525 vs 3378, p=0.0317), Fig. Two were semi-quantitative: Beckman Access SARS-CoV-2 IgG II (Beckman Coulter France SAS, Roissy CDG, France) with 30 AU/ml as a threshold for positivity and Siemens Atellica IM SARS-CoV-2 IgG (Siemens Healthcare SAS, Saint-Denis, France) with 0.8 AU/ml used as a threshold for positivity. It also markedly reduced viral RNA burden in serum and tissues. This research focuses on the impacts of the S protein. Methods Protoc. Statistical analysis was performed to compare the GMT of micro-VNT50 between 1 and 10 g dosed mice at each time point. While most serologic assays are qualitative, a quantitative serologic . More info. The nonparametric KruskalWallis test for multiple comparisons was used to compare all assays. Nat Commun 14, 2309 (2023). All patients had received at least one dose of either Pfizer/BioNTech BNT162b2 or Moderna COVID-19 vaccine (Spikevax): 60 patients received Pfizer vaccine (87%) and 9 received Moderna vaccine (13%). PLoS ONE 18(4): Article There are currently a few monoclonal antibody cocktails (such as bamlanivimab, casirivimab, and imdevimab together) that have been authorized by the US FDA for emergency use for the treatment of COVID-19 in certain population and similar medications have been authorized in other countries. Folegatti, P. M. et al. Bowen, J. E. et al. Cite this article. Protection against WT (Wuhan-Hu1) viral challenge in K18-hACE2 transgenic mice mediated by ChulaCov19 was successfully demonstrated. In the challenge study, NAb was also assessed by live-virus microneutralization test against strain hCoV-19/Hongkong/VM20001061/2020 with slightly different incubation period and detection technique. The comparable molecular weight of S0 expressed by ChulaCov19 was also observed when using commercial recombinant S with S1/S2 cleavage site abolished as control (Fig. Protection against COVID-19 is thought to depend on the presence of specific antibodies against the virus, as well as the function of other components of the immune system such as T cells. SARS-CoV-2 Spike Protein Reduces Burst Activities in Neurons Measured by Micro-Electrode Arrays, Omicron spike N679K mutation acts as a loss-of-function mutation attenuating SARS-CoV-2 in vitro & in vivo, The virological characteristics of XBB.1.16. Reactive (Positive, 50.0 AU/mL) results may be due to immunization or past or present infection with SARS-CoV-2. 4d). Kim, H. W. et al. Citation: Halfon P, Jordana S, Blachier S, Cartlamy P, Kbaier L, Psomas CK, et al. Adv. The WHO International Standard for COVID-19 serological tests: towards This elicited immunogenicity is significantly higher than those induced by homologous CoronaVac or AZD1222 vaccination. Zheng, C. et al. p<0.05 and p<0.01 are indicated by * and **, respectively. Comparative immunogenicity and reactogenicity of heterologous ChAdOx1-nCoV-19-priming and BNT162b2 or mRNA-1273-boosting with homologous COVID-19 vaccine regimens. This was consistent with the prior study in K18-hACE2 that intranasal inoculation with the similar range of virus caused death within 1 week22. p<0.05 and p<0.01 are indicated by * and **, respectively. NAb measurements in mice sera from Experiment 1 against WT (Wuhan-Hu1) live-virus (micro-VNT50) at 2-week after each dose showed NAb response in a dose-dependent manner. This was in accordance with previous studies showing that survived animals, either using HFH4-hACE2 or K18-hACE2 strains, could recovery their body weight to the basal levels at pre-challenge while weight lost continued for unprotected or non-vaccinated animals and reached euthanized criteria within approximately 1 week24,25,26. Sera were collected at weeks 0, 2, 3, 4+6 days, and 5+6 days for NAb measurements. ADS The GMT of micro-VNT50 titers at week 5 were 15,343 and 4424 in the 10 g and 1 g groups, respectively, p=0.0325. Mean spike-specific IFN- positive T cells for 0.2, 1, 10 and 30g were 166, 429, 1913, and 1378 SFC/106 splenocytes, respectively. In the clinical setting, >8 weeks interval for AZD1222 was recommended to maximize the vaccine efficacy52. Experiment 1: dose-response of homologous ChulaCov19 prime/boost study, mice were immunized twice intramuscularly at 3 weeks interval of ChulaCov19 with dosage ranging from 0.2, 1, 10, to 30g. 7, eabi5246 (2021). \1;nJ/mjJ=DqXlU,u>z}x)tU#K>/#}idN"%W$YoSA14Ys5+VlE5-3a+`h"xD%5n#L$\g%[&0Gy-x;a>$'+6#am#WK>nxW|^E~YS t4G2G9V$Mf=E5y? https://doi.org/10.1038/s41467-023-37795-0, DOI: https://doi.org/10.1038/s41467-023-37795-0. WHO. Role of antigen, CD8, and cytotoxic T lymphocyte (CTL) avidity in high dose antigen induction of apoptosis of effector CTL. To detect SARS-CoV-2 RNA localization in mouse tissues samples, FFPE tissues of lung and nasal cavity were performed by using RNAscope In situ hybridization (ISH) assay. Neurological phenotypes induced by SARS-CoV-2 spike protein in neurons Developing highly effective vaccine platforms like mRNA technology in low- and middle-income countries (LMICs) is therefore an important goal21. In contrast, ChulaCov19 immunized mice, both 1g and 10g doses enabled 100% survival compared to full mortality rate in PBS-immunized mice. The outcome strongly suggests that the RBD itself is sufficient to suppress surge activities. Alexander-Miller, M. A., Leggatt, G. R., Sarin, A. Experiments were repeated two times independently with similar results. E.P., C.K., D.W., and K.R. The particles were re-characterized at 6- and 12-month after manufacture for stability assessment. An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. This test should not be used to diagnose or exclude acute SARS-CoV-2 infection. In the present study, researchers quantified the neurological phenotypes induced in neurons by the SARS-CoV-2 S protein. A SARS-CoV-2 probe (RNAscope Probe, V-nCoV2019-S, Advanced Cell Diagnostics ACD, Newark, CA (ACD, 848561)) was used. mRNA encapsulation was performed by Genevant Sciences Corporation (Vancouver, British Columbia, Canada). [ view less ], Affiliations: James Heyes, A. J., Kieu Mong, L. A. M., Alan, D. MARTIN. The Wilcoxon test for pairwise comparisons yielded P < 0.0001 for all comparisons. Few studies have highlighted the lack of standardization of SARS-CoV-2 serology, despite the use of the international standards set by the World Health Organization (WHO) for SARS-CoV-2 immunoglobulin levels (BAU/ml) [1013]. There is also a limitation regarding the two semi-quantitative antibody binding assays as a saturation limit could be reached because of their limited measurement range. PN20-06). Labcorp offers both semi-quantitative and qualitative options for testing for spike protein antibodies. Calculations were performed using the SAS V9.4 software (SAS Institute Inc., Cary, NC, USA).
